Business Context and Reporting Period
This Form 8-K was filed by Nemus Bioscience, Inc. (noted as Skye Bioscience, Inc. in metadata) on January 10, 2017. The report details the entry into a Material Definitive Agreement with the University of Mississippi, School of Pharmacy (UM).
Key Financial Metrics
The filing does not provide specific revenue, profit, cash flow, margin, debt, or liquidity figures. It outlines the financial obligations associated with the new license agreement:
- Upfront Fees: The Company is obligated to pay upfront license fees (specific amount not disclosed).
- Milestone Payments: Aggregate contingent milestone payments total $700,000 upon achievement of development and regulatory milestones.
- Royalties: Royalties on net sales are in the mid-single digits.
- Annual Maintenance Fees: Required annually and credited against royalties in the current fiscal year.
- Sublicensing: The Company must pay UM a portion of licensing fees received from sublicensees, subject to a minimum royalty.
Material Changes
The primary material change is the execution of an exclusive, perpetual license agreement for intellectual property related to UM5070, a platform of cannabinoid-based molecules. This agreement follows approximately one year of screening and target molecule identification studies focused on therapy-resistant infectious organisms, such as methicillin-resistant Staphylococcus aureus (MRSA).
Outlook, Risks, and Contingencies
Management Commentary and Outlook: The agreement grants the Company the right to research, develop, and commercialize products for infectious diseases. The license term continues until the later of the expiration of the last patent or the end of payment obligations.
Risks and Termination: UM may terminate the agreement if the Company fails to pay material amounts, materially breaches covenants, fails to comply with terms, undergoes bankruptcy, dissolves, or fails to make reasonable efforts to commercialize at least one product within one year of the first commercial sale. The Company may terminate the agreement with 60 days' written notice.
Investor Verification Checklist
- Verify the exact amount of the upfront license fees payable to the University of Mississippi.
- Confirm the specific "mid-single digit" royalty percentage and the definition of "net sales" used in the agreement.
- Review the specific development and regulatory milestones required to trigger the $700,000 in contingent payments.
- Examine the full text of the License Agreement filed as an exhibit to the Form 10-K for the fiscal year ended December 31, 2016.
- Assess the Company's current cash position to determine its ability to fund the upfront fees and annual maintenance fees.